<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03096639</url>
  </required_header>
  <id_info>
    <org_study_id>P-200</org_study_id>
    <nct_id>NCT03096639</nct_id>
  </id_info>
  <brief_title>Percutaneous Temporary Placement of a Phrenic Nerve Stimulator for Diaphragm Pacing</brief_title>
  <acronym>RESCUE2</acronym>
  <official_title>Percutaneous Temporary Placement of a Phrenic Nerve Stimulator for Diaphragm Pacing</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lungpacer Medical Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Syntactx</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Lungpacer Medical Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized clinical trial to investigate the use of the temporary Diaphragm Pacing Therapy&#xD;
      System (DPTS) to rehabilitate the diaphragm in mechanically ventilated patients who have&#xD;
      failed at least two weaning attempts. The goal is to strengthen and rehabilitate the&#xD;
      diaphragm to liberate the patient more quickly from mechanical ventilation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Mechanical ventilation (MV) is a life saving technology but can also cause damage to the&#xD;
      lungs and diaphragm such as ventricular induced diaphragmatic dysfunction (VIDD). Research&#xD;
      has shown that after being on mandatory MV and sedated the diaphragm begins to atrophy within&#xD;
      as short as 18 hours. The Lungpacer Diaphragm Pacing Therapy System (DPTS) is a temporary&#xD;
      therapy that consists of the Lungpacer IntraVenous Electrode Catheter (LIVE Catheter) and the&#xD;
      Lungpacer Control Unit system. The LIVE Catheter is a proprietary central venous catheter&#xD;
      that incorporates pacing electrodes in strategic areas that align with the left and right&#xD;
      phrenic nerves. The LIVE Catheter can also be used for fluid delivery like any other central&#xD;
      venous catheter. The randomized clinical trial will investigate the safety, effectiveness and&#xD;
      performance of the Lungpacer DPTS. By stimulating the diaphragm through daily therapy&#xD;
      sessions, with the intention of exercising and rehabilitating the diaphragm muscle so the&#xD;
      patient may be able to be more quickly liberated from MV. The patient population includes&#xD;
      those who have been mechanically ventilated for greater than or equal to 96 hours (4days),&#xD;
      have failed two or more spontaneous breathing trials (SBT), and were not hypervolemic during&#xD;
      the latest spontaneous breathing trial. Patients must have resolution of the initial&#xD;
      indication for placement on mechanical ventilation before entering the trial.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 14, 2017</start_date>
  <completion_date type="Actual">January 30, 2020</completion_date>
  <primary_completion_date type="Actual">December 29, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>1:1 randomization of treatment and control group</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>The ultrasound core lab reviewers will be blinded to study allocation groups</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion successfully weaned by 30 days for subjects randomized to Treatment (Lungpacer DPTS) as compared to subjects randomized to Control.</measure>
    <time_frame>Patients will be allowed to stay in the study for up to 30 (+2 days of follow up for adverse events) days if not removed from mechanical ventilation sooner</time_frame>
    <description>&quot;Successfully weaned&quot; is defined as passing the protocol-specific Ventilator Liberation Trial (VLT), or removed from MV, and not reintubated (subjects with an oral or nasal, endotracheal tube) or returned to MV (subjects with a tracheostomy) within 48 hours</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Days on mechanical ventilation</measure>
    <time_frame>from randomization to 30 days</time_frame>
    <description>Days on mechanical ventilation from randomization to removal from MV associated with successful weaning or Day 30, whichever comes first</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in diaphragmatic thickening fraction on diaphragm ultrasound</measure>
    <time_frame>to successful weaning or on day 30 which ever comes first.</time_frame>
    <description>Evaluate difference in changes in diaphragmatic thickening fraction between study allocation groups from randomization to successful weaning or on day 30 whichever comes first;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in MIP</measure>
    <time_frame>to successful weaning, or on day 30, whichever comes first.</time_frame>
    <description>Change in MIP from randomization to last available measure; Change in MIP over time from randomization (baseline).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in MIP</measure>
    <time_frame>to successful weaning, or on day 30 whichever comes first.</time_frame>
    <description>Rate of MIP change per day from randomization (baseline) to last available measure;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in RSBI</measure>
    <time_frame>to successful weaning, or on day 30, whichever comes first</time_frame>
    <description>Change in RSBI from randomization (baseline) to last available measure; Change in RSBI over time from randomization (baseline);</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in RSBI</measure>
    <time_frame>to successful weaning, or on day 30, whichever comes first</time_frame>
    <description>Rate of RSBI change per day from randomization (baseline) to last available measure;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>on day 30</time_frame>
    <description>30-day mortality</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Weaning from and re-installation of Mechanical Ventilation in both groups</measure>
    <time_frame>from randomization to 30 days</time_frame>
    <description>Cessations and re-instatements of mechanical ventilation to Day 30 or Study Exit</description>
  </other_outcome>
  <other_outcome>
    <measure>Tracheostomy</measure>
    <time_frame>from randomization to 30 days</time_frame>
    <description>Proportion of subjects tracheotomized from randomization to study exit</description>
  </other_outcome>
  <other_outcome>
    <measure>Ventilator settings</measure>
    <time_frame>from randomization to 30 days</time_frame>
    <description>Pressure Support daily, to last available measure</description>
  </other_outcome>
  <other_outcome>
    <measure>Ventilator settings</measure>
    <time_frame>from randomization to 30 days</time_frame>
    <description>PEEP daily, to last available measure</description>
  </other_outcome>
  <other_outcome>
    <measure>Ventilator settings</measure>
    <time_frame>from randomization to 30 days</time_frame>
    <description>Ventilation Mode daily, to last available measure</description>
  </other_outcome>
  <other_outcome>
    <measure>Ventilator settings</measure>
    <time_frame>from randomization to 30 days</time_frame>
    <description>Tidal Volume daily, to last available measure</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of ICU admissions and discharges through D30 for both groups</measure>
    <time_frame>from randomization to 30 days</time_frame>
    <description>ICU admissions and discharges to day 30</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of hospital admissions and discharges through D30 for both groups</measure>
    <time_frame>from randomization to 30 days</time_frame>
    <description>Hospital admissions and discharges to day 30.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">110</enrollment>
  <condition>Ventilator Induced Diaphragm Dysfunction</condition>
  <arm_group>
    <arm_group_label>Diaphragm Pacing Therapy DPTS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Diaphragm Pacing intervention will be conducted 2x a day using the Diaphragmatic Pacing Therapy System (DPTS). The DPTS includes the Lungpacer IntraVenous Electrode Catheter (LIVE Catheter) which is inserted temporarily into the left subclavian vein, the Lungpacer Control Unit (LCU external unit) and an intermediate cable that connects the LCU to the LIVE Catheter.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard of care treatment of weaning failure, no intervention is involved in this control group.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Diaphragmatic Pacing Therapy DPTS</intervention_name>
    <description>Subjects will undergo DPTS 2 times a day until successfully extubated with no reintubation within 48 hours.</description>
    <arm_group_label>Diaphragm Pacing Therapy DPTS</arm_group_label>
    <other_name>DPTS</other_name>
    <other_name>LIVE Catheter</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18 years of age or older&#xD;
&#xD;
          -  have been mechanically ventilated for &gt; or = to 96 hours (4 days), and&#xD;
&#xD;
          -  have satisfied the Readiness-to-Wean criteria and&#xD;
&#xD;
          -  have failed at least two VLTs, one of which is the study specific VLT.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  currently on extracorporeal membrane oxygenation (ECMO);&#xD;
&#xD;
          -  weaning failure due to hypervolemia;&#xD;
&#xD;
          -  medical history or known anatomy that prevents insertion of the LIVE Catheter into the&#xD;
             left subclavian vein;&#xD;
&#xD;
          -  currently being treated with neuromuscular blockade;&#xD;
&#xD;
          -  clinically overt congestive heart failure that is preventing weaning;&#xD;
&#xD;
          -  pre-existing neuromuscular diseases that could affect the respiratory muscles;&#xD;
&#xD;
          -  pre-existing severe chronic pulmonary fibrosis;&#xD;
&#xD;
          -  pleural effusions occupying greater than one third of the pleural space on either&#xD;
             side;&#xD;
&#xD;
          -  BMI &gt; or = 40;&#xD;
&#xD;
          -  known or suspected phrenic nerve paralysis;&#xD;
&#xD;
          -  any electrical device (implanted or external) that may be prone to interaction with or&#xD;
             interference from the Lungpacer DPTS including neurological pacing/stimulator devices,&#xD;
             cardiac pacemakers and defibrillators;&#xD;
&#xD;
          -  prior bacteremia reported within the last 48 hours;&#xD;
&#xD;
          -  current hemodynamic instability, sepsis or septic shock;&#xD;
&#xD;
          -  terminally ill with 6 months or less life expectancy or not committed to full care;&#xD;
&#xD;
          -  known or suspected to be pregnant or lactating; and&#xD;
&#xD;
          -  currently being treated in another clinical trial studying an experimental treatment&#xD;
             that could affect the study primary outcome.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Linda H Clark, BSN</last_name>
    <role>Study Director</role>
    <affiliation>Vice President of Clinical Affairs, Lungpacer Medical, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU Angers, Reanimation Medicale</name>
      <address>
        <city>Angers</city>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Louis-Mourier</name>
      <address>
        <city>Colombes</city>
        <zip>92700</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Montpellier</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Nice (CHU Nice)</name>
      <address>
        <city>Nice</city>
        <zip>06001</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Europeen Georges-Pompidou</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pitie Salpetriere Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75651</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire CHU</name>
      <address>
        <city>Strasbourg</city>
        <zip>67000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uniklinik RWTH Aachen</name>
      <address>
        <city>Aachen</city>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heart and Diabetes Center Bad Oeynhausen</name>
      <address>
        <city>Bad Oeynhausen</city>
        <zip>32545</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charite Universitatsmedizin Berlin - Mitte campus</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Bonn</name>
      <address>
        <city>Bonn</city>
        <zip>53105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinik Dresden</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsmedizin Gottingen, Georg-August-Universitat</name>
      <address>
        <city>Gottingen</city>
        <zip>37075</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asklepios Kliniken Hamburg GmbH - Asklepios Klinikum Harburg</name>
      <address>
        <city>Hamburg</city>
        <zip>21075</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Hamburg-Eppendorf (UKE)</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Med Uni-Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>69126</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Jena</name>
      <address>
        <city>Jena</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Nuernberg</name>
      <address>
        <city>Nuernberg</city>
        <zip>90419</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Regensburg</name>
      <address>
        <city>Regensburg</city>
        <zip>93053</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fachkrankenhaus Kloster Grafschaft</name>
      <address>
        <city>Schmallenberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wissenschaftliches Institut Bethanien fur Pneumologie e.V.</name>
      <address>
        <city>Solingen</city>
        <zip>42699</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>March 15, 2017</study_first_submitted>
  <study_first_submitted_qc>March 24, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 30, 2017</study_first_posted>
  <last_update_submitted>September 30, 2020</last_update_submitted>
  <last_update_submitted_qc>September 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diaphragm atrophy</keyword>
  <keyword>VIDD</keyword>
  <keyword>Weaning failure</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Only investigators participating in this clinical trial will be able to see final de-identified participant data at the completion of the study and it will be available through the clinical research organization (CRO).</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

